Alzheimer Disease, Brain Diseases, Major Depressive Disorder, Neuro-Degenerative Disease, PTSD, Treatment Resistant Depression
Conditions
Keywords
NMDA, PTSD, Alzheimer's disease, Brain Diseases, Neuro-Degenerative Disease, Major Depressive Disorder, Treatment Resistant Depression
Brief summary
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: * What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)? * What is the PK profile of single ascending doses of the FENM in human? * What is the preliminary exploratory time course of Brain Disease Neurotrophic Factor (BDNF) plasmatic levels of single ascending doses of the FENM? Participants will receive one single oral dose of FENM.
Interventions
DRUGFluoroethylnormemantine (FENM)
Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
Sponsors
ReST Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* willing and able to sign written informed consent, * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, a total body weight \>65 kg, * efficient contraceptive mean, * no major psychiatric disorder per the Mini-International Neuropsychiatric Interview (MINI) questionnaire, * normal laboratory tests results, arterial Blood Pressure/pulse rate, 12-lead Electrocardiogram recording.
Exclusion criteria
* evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic disease including drug allergies, or other severe acute or chronic medical or psychiatric condition or laboratory abnormality, * history of febrile illness within 5 days prior to administration, * any condition possibly affecting drug absorption, * using of prescription drugs, vaccine, routine or as needed consumption of medications or herbal supplements, * having positive serology, positive urine test for drugs of abuse, a general medical or psychological condition or behavior, including current substance dependence or abuse, * history of drug or alcohol abuse within 1 year before screening, * consuming currently of nicotine containing products, any food or any beverage containing grapefruit or grapefruit juice within 48 h prior to administration, * having blood donation or loss of significant amount of blood within 2 months prior to study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | From single dose administration to the end of the study follow-up (2 weeks later) |
Secondary
| Measure | Time frame |
|---|---|
| To assess time to Cmax [Tmax] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess minimum concentration within the dosing interval [Cmin] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess last observed plasma concentration [Clast] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess time of the minimum concentration [Tmax] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess area under the plasma concentration-time curve from 0 to the end of the dose interval [AUC 0-tau] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess maximum plasma concentration [Cmax] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess total area under the plasma concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large (infinity) [AUC 0-∞] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess terminal half-life, apparent elimination half-life [T1/2] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess apparent oral clearance [CL/F] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess apparent volume of distribution [Vz/F] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
| To assess preliminary exploratory time course of Brain Disease Neurotrophic Factor plasmatic levels of single ascending doses of the FENM | At pre-dose, at Cmax (estimated at 6-8hours post-dose) and at 48, 72 and 264hours post-dose |
| To assess area under the plasma concentration-time curve from dosing (time 0) to the time of last measured concentration [AUC 0-last] | At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose |
Countries
Belgium
Outcome results
None listed